Evaluation of an Opioid Decrease Strategy in Chronic

Completed

• Conditions: Chronic Pain
• Interventions: Drug: opioid withdrawal

• Registration Number: NCT04424459
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

Increase in the consumption of analgesics observed in many countries with a mediatic crisis resulting in an increasingly frequent wish of patients to wean themselves from opiates. A recent update (B. Rolland 2017) suggests that upon initiation of an opioid analgesic treatment, the patient should be informed of the risk of opioid dependence and misuse. There is no clearly validated decay scheme in the event of dependence in patients with Chronic Non-Cancer Pain.

Hypotheses:

* Possibility of a rapid decrease in opioid analgesic treatments at DCNC sensitized to the risk of DOP and MOP. (Protocol implemented: Multidisciplinary assessment, workshops and information sheet on chronic pain, treatments and risk of DOP, pharmacological and nonpharmacological adaptation)

* Highlight the need for additional information from patients and prescribers on the risk of DOP and MOP in DCNC.

Detailed Description

Main objective: Check if the rapid to semi-rapid regimen (- 25 to -60% dosage in 5 days of HDS) of opioid analgesics, without the use of methadone or buprenorphine agonists, in the case of DCNC at the CETD in Montpellier is efficient in the medium term (6 months).

Secondary objective:

* With our inclusion questionnaire we wanted to check if the patients had been made aware of the risk of opiate dependence and misuse.

* Detect the conditions of prescriptions that can promote the misuse of opiates.

* Evaluating the different components of residual pain at 6 months (type, intensity, anxiety component and depression, function).

Study Timeline

• Study Start: 2019-10-01
• Study First Submitted: 2020-05-28
• Study First Submitted QC: 2020-06-09
• Study First Posted: 2020-06-11
• Primary Completion: 2020-07-01
• Study Completion: 2020-07-30
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-28
• Last Update Posted: 2020-12-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients included from 10/01/19 to 12/31/19.	opioid withdrawal	Patients included from 10/01/19 to 12/31/19. (the study will be extended to a larger number of patients according to the first results), continued according to the first results. DCNC patients treated at the Montpellier Pain Assessment and Treatment Center hospitalized during the period from 10/01/19 to 12/31/19, for misuse of opioid treatment.

Primary Outcome Measures

Name	Time	Method
Change of the dosage of opioid and co-analgesic treatments	3 months and 6 months	Change of the dosage of opioid and co-analgesic treatments

Secondary Outcome Measures

Name	Time	Method
Measuring quality of life	Inclusion, 3 and 6 months	interview with the patient

Trial Locations

Locations (1)

Uhmontpellier; 🇫🇷 Montpellier, France